PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
about
Markers of resistance to anti-EGFR therapy in colorectal cancerBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASClinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancerPI3K inhibitors as new cancer therapeutics: implications for clinical trial designMolecular phenotypes of colorectal cancer and potential clinical applicationsPIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.Mechanisms of resistance to anti-EGFR therapy in colorectal cancerMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer DevelopmentAspirin use, tumor PIK3CA mutation, and colorectal-cancer survivalPCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysisColorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology ApproachPrognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysisClinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patientsKRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancerHigh-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations.EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updatePIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type statusPIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal CancerDownregulation of miR203 induces overexpression of PIK3CA and predicts poor prognosis of gastric cancer patients.BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP methodA rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signaturePrevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.PIK3CA mutation detection in metastatic biliary cancer using cell-free DNAMutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.
P2860
Q24598640-91906D18-AC03-4A24-A7DE-E55DE5A94540Q26766535-A826263C-2AF2-4162-B868-530AFD9EBF54Q26769958-4B43F747-D962-4D2F-B2E6-4137ED7172A6Q26770489-31436C20-627D-4FE9-B43B-9F2D9EC0FBB6Q26785725-2E94C3A5-6EA3-463E-9E15-FD9C45200822Q27852105-250DA51F-2192-4A77-B28D-AB049336D6A4Q27852970-285FE54B-D843-47A4-8509-5E47FD2759E8Q28074073-172064EF-AAF5-46EF-A54C-A55BF6950C3AQ28076490-EE8B7CB4-D4BE-411F-8874-BB5EE67C1A8EQ28077545-ADBCC362-C88B-48A8-8D20-44EA40FE02E8Q28115416-7D5046D8-84EC-4649-869B-99DC66CCACAAQ28277824-ABE35B22-7A42-4B8D-886A-15495E172EC1Q28543278-4B25B11F-1549-401D-9983-FFB2C36705F6Q28647615-420EF725-7D4B-48D6-8B3F-A9D661EFA656Q30248900-6C32BB87-5909-41E0-99C6-4C566BCE0E00Q33574315-AA3CB11C-08EE-4187-AF66-21E31E08AF68Q33682988-670C1B14-53AD-4D46-9B28-34C27A2F4078Q34051967-3DF10C13-AE9D-48E2-B7F1-601CAC2015A8Q34078212-A09B24D9-7DBA-44DD-B735-BE21512F4019Q34269163-894E7F76-6D9A-4892-8427-0EE6233412DAQ34369027-2201FD7C-A75C-4249-8693-34A5A6747AD9Q34381843-08AF1BC7-1F08-48EA-8510-B477D5B338ADQ34441837-AF393698-0347-465C-8305-7E9429F8DE69Q34778710-87609F6A-9C26-4D29-A4D2-8D8517E43672Q35067570-13B1FC19-BB49-449D-9D3D-F4AB8122782EQ35137474-30CE0852-9798-4447-8003-75E3523DE368Q35815544-1E69BD9B-144F-4A3A-819A-39F23C6325D8Q35871739-C13A46C0-522A-4FB0-9F6E-E0D2AC37149DQ35962621-54867EF2-B8DB-4825-B209-35CAF5464F23Q36074183-7B5EC39D-B130-4D31-8079-28D7B316E026Q36093324-FDBD1664-EE3F-491D-9DF5-FDFA35345D1BQ36108299-BA369A9C-372D-4BD9-B471-CCE6418ED113Q36201032-42DE46E1-97E5-4C01-8AC7-732983D5FCB7Q36210809-D273A5E0-002F-4443-B41A-DFCED2CC63C7Q36346491-DBAE3BC3-8545-47E5-A83D-9AF961576672Q36393095-DD44F89C-EB36-48BA-A95D-7A6F508CDCB0Q36545534-06CD4D93-D1B7-4845-9317-F1604D71313CQ36905878-BE465322-F7EB-4FBB-A438-00F9C4AF6F65Q37360360-EF9CE05B-003E-4547-8CAB-9DB1FDA9A2BDQ37525272-9945D72A-515F-4458-B646-A0BE01092A56
P2860
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@ast
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@en
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@nl
type
label
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@ast
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@en
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@nl
prefLabel
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@ast
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@en
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@nl
P2093
P2860
P31
P921
P3181
P356
P1433
P1476
PIK3CA exon 20 mutations as a ...... matic review and meta-analysis
@en
P2093
P2860
P304
P3181
P356
10.1093/ANNONC/MDR464
P407
P577
2012-06-01T00:00:00Z